Drug Trial Radar · NCT06282458
Dose-Finding Study Evaluating Effect on Body Composition of Enobosarm in Patients Taking a GLP-1 for Chronic Weight Mgmt
Last checked: Nov 19, 2026Latest source record: Sep 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
168
Actual
Start
Apr 29, 2024
Primary completion
Apr 11, 2025
Study completion Aug 22, 2025
Sponsor
- Lead sponsor
- Veru Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 60 years, up to 100 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this study is to assess the effect of enobosarm on total lean mass as measured by DEXA in patients maintained on GLP-1 receptor agonists.
Conditions
- Muscle Loss
- Obesity
Interventions
EnobosarmDrug
Enobosarm is an oral, new chemical entity class, SARM, that has demonstrated tissue-selective, dose-dependent improvement in body composition with increases in muscle mass and reduces fat mass, improves insulin resistance, has no masculinizing effects in women, has neutral prostate effects in men, and no increases in hematocrit. Increases in muscle mass have resulted in improvements in muscle strength and physical function.
SemaglutideDrug
Semaglutide for Chronic Weight Management
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint for the study is the percentage change from baseline in total lean body mass at 112 days.Time frame: Day 112
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Pinnacle Trials
Anniston, Alabama
Cullman Clinical Trials
Cullman, Alabama
Artemis Institute for Clinical Research
San Diego, California
Universal Axom Clinical Research
Doral, Florida
Altus Research
Lake Worth, Florida
MARC Research Center
Louisville, Kentucky
Pennington Biomedical
Baton Rouge, Louisiana
DelRicht Research - New Orleans
New Orleans, Louisiana
Centennial Medical Group (CMG)
Elkridge, Maryland
SKY Integrative Medical Center
Ridgeland, Mississippi
Clinvest Headlands LLC
Springfield, Missouri
Palm Research Center
Las Vegas, Nevada
Lillestol Research LLC
Fargo, North Dakota
Clinical Trials of Texas, LLC DBA Flourish Research
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.